Ulrich Dauer has been Vivoryon’s Chief Executive Officer since May 2018. He has had a career spanning more than 20 years in the biopharmaceutical industry in both public and private companies.
As one of the founders, Ulrich Dauer previously worked as CEO of 4SC AG for 14 years, attracting multiple private and, upon the company’s IPO at the Prime Standard of the Frankfurt Stock Exchange in 2005, public investors. Under his leadership, 4SC closed multiple industry partnerships with international biopharmaceutical companies. In subsequent leadership positions in the biotech industry, he executed the €130 million trade sale of Activaero in 2014 and later took up CEO positions of two privately held biotech companies (Omeicos GmbH, Ventaleon GmbH).
Ulrich Dauer holds a PhD in Chemistry from the Julius Maximilians University of Würzburg, Germany.
As one of the founders, Ulrich Dauer previously worked as CEO of 4SC AG for 14 years, attracting multiple private and, upon the company’s IPO at the Prime Standard of the Frankfurt Stock Exchange in 2005, public investors. Under his leadership, 4SC closed multiple industry partnerships with international biopharmaceutical companies. In subsequent leadership positions in the biotech industry, he executed the €130 million trade sale of Activaero in 2014 and later took up CEO positions of two privately held biotech companies (Omeicos GmbH, Ventaleon GmbH).
Ulrich Dauer holds a PhD in Chemistry from the Julius Maximilians University of Würzburg, Germany.
Speaking In
10:15 AM - 10:30 AM (EST)
Monday, February 6
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule…
Music Box